Items Tagged ‘Locally Advanced Stage III (C) Prostate Cancer’

February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


October 29th, 2015

Gene-Targeted Drug Can Treat Prostate Cancer

By

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib, the world’s first drug to reach the market targeted against inherited cancer mutations, was found […]

View full entry

Tags: advanced, DNA repair mutations, genomic testing, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, olaparib, Prostate Cancer, treatment-resistant


August 17th, 2015

Two-drug combination boosts survival in metastatic prostate cancer

By

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial led by a Dana-Farber Cancer Institute scientist. Patients who underwent six cycles of treatment with the chemotherapy […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer


January 20th, 2015

Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer

By

According to the results of a study recently published in the Journal of Clinical Oncology, the addition of radiation treatment to treatment with androgen-deprivation therapy (ADT) in older men with locally advanced prostate therapy prolongs survival when compared to treatment with androgen-deprivation therapy alone. The researchers reported that ADT plus radiation reduced cancer deaths by […]

View full entry

Tags: adt, androgen deprivation therapy, Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer, radiation therapy


December 10th, 2014

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations

By

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment of the disease.  Both studies were presented, December 3, at the Society of Urologic Oncology (SUO) Annual Meeting, in […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, oncotype, Prostate Cancer, risk, treatment


September 11th, 2014

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives

By

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs) that support them. The majority (64 percent) of patients surveyed report that their prostate cancer diagnosis […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, quality of life, Refactory/Recurrent Prostate Cancer


June 18th, 2014

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer

By

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in metastatic prostate cancer patients who had been resistant to initial hormone therapy. Cells in the prostate gland have testosterone receptors and when […]

View full entry

Tags: hormone therapy, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi, zytiga


February 27th, 2014

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer

By

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries, and, in those receiving radiotherapy, secondary malignancies. These results were published in The Lancet Oncology. The treatment of prostate cancer can cause lasting […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


September 4th, 2013

Metformin May Improve Survival in Diabetic Men with Prostate Cancer

By

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate cancer is the most commonly diagnosed cancer (other than skin cancer) in U.S. men. Each year, […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


June 19th, 2013

ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery

By

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have issued a joint guideline regarding the use of radiation therapy after prostatectomy. It marks the first time the two medical organizations—most responsible for prostate treatment—have issued a joint guideline. The 81-page document—a collaborative effort of many experts in the field—is a comprehensive […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


May 13th, 2013

Genomic Test May Help Guide Prostate Cancer Treatment

By

A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of disease in a validation study presented at the 2013 annual meeting of the American Urological Association in San Diego, […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


March 7th, 2013

Early Radiation Improves Prostate Cancer Survival

By

Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, Florida. Prostate cancer is the most commonly diagnosed cancer (other than skin cancer) in U.S. […]

View full entry

Tags: Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer


January 28th, 2013

No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer

By

Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most commonly diagnosed cancer (other than skin cancer) in U.S. men. Each year, more than 240,000 men are diagnosed […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


November 15th, 2012

Viagra Improves Sexual Function after Radiation for Prostate Cancer

By

Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for Radiation Oncology in Boston, Massachusetts. Prostate cancer is the most commonly diagnosed type of cancer (other than skin cancer) in […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer


September 18th, 2012

Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment

By

Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New England Journal of Medicine. Hormone therapy—also called androgen deprivation therapy—is designed to block testosterone from stimulating the […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer